207 related articles for article (PubMed ID: 33551801)
1. The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.
Li XX; Kumar V; Clark RJ; Lee JD; Woodruff TM
Front Pharmacol; 2020; 11():591398. PubMed ID: 33551801
[TBL] [Abstract][Full Text] [Related]
2. Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections.
Muenstermann M; Strobel L; Klos A; Wetsel RA; Woodruff TM; Köhl J; Johswich KO
Virulence; 2019 Dec; 10(1):677-694. PubMed ID: 31274379
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Anaphylatoxin Receptor Expression and C3a/C5a Functions in Anaphylatoxin Receptor Reporter Mice.
Laumonnier Y; Karsten CM; Köhl G; Köhl J
Curr Protoc Immunol; 2020 Sep; 130(1):e100. PubMed ID: 32710701
[TBL] [Abstract][Full Text] [Related]
4. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
Li XX; Clark RJ; Woodruff TM
Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
[TBL] [Abstract][Full Text] [Related]
5. C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages.
Li XX; Clark RJ; Woodruff TM
J Immunol; 2020 Aug; 205(4):1102-1112. PubMed ID: 32611725
[TBL] [Abstract][Full Text] [Related]
6. Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain.
Morgan M; Deuis JR; Woodruff TM; Lewis RJ; Vetter I
Mol Immunol; 2018 Feb; 94():68-74. PubMed ID: 29274925
[TBL] [Abstract][Full Text] [Related]
7. Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins.
Wang Y; Liu W; Xu Y; He X; Yuan Q; Luo P; Fan W; Zhu J; Zhang X; Cheng X; Jiang Y; Xu HE; Zhuang Y
Nat Chem Biol; 2023 Nov; 19(11):1351-1360. PubMed ID: 37169960
[TBL] [Abstract][Full Text] [Related]
8. TLQP-21 is a low potency partial C3aR activator on human primary macrophages.
Li XX; Lee JD; Lee HS; Clark RJ; Woodruff TM
Front Immunol; 2023; 14():1086673. PubMed ID: 36776827
[TBL] [Abstract][Full Text] [Related]
9. IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.
Orrem HL; Nilsson PH; Pischke SE; Kleveland O; Yndestad A; Ekholt K; Damås JK; Espevik T; Bendz B; Halvorsen B; Gregersen I; Wiseth R; Andersen GØ; Ueland T; Gullestad L; Aukrust P; Barratt-Due A; Mollnes TE
Front Immunol; 2018; 9():2035. PubMed ID: 30258440
[No Abstract] [Full Text] [Related]
10. C3aR and C5aR1 act as key regulators of human and mouse β-cell function.
Atanes P; Ruz-Maldonado I; Pingitore A; Hawkes R; Liu B; Zhao M; Huang GC; Persaud SJ; Amisten S
Cell Mol Life Sci; 2018 Feb; 75(4):715-726. PubMed ID: 28921001
[TBL] [Abstract][Full Text] [Related]
11. C3aR Antagonist Alleviates C3a Induced Tubular Profibrotic Phenotype Transition via Restoring PPARα/CPT-1α Mediated Mitochondrial Fatty Acid Oxidation in Renin-Dependent Hypertension.
Wang C; Wang Z; Xu J; Ma H; Jin K; Xu T; Pan X; Feng X; Zhang W
Front Biosci (Landmark Ed); 2023 Oct; 28(10):238. PubMed ID: 37919077
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.
Emtenani S; Holtsche MM; Stahlkopf R; Seiler DL; Burn T; Liu H; Parker M; Yilmaz K; Dikmen HO; Lang MH; Sadik CD; Karsten CM; van Beek N; Ludwig RJ; Köhl J; Schmidt E
Front Immunol; 2022; 13():942493. PubMed ID: 36466856
[TBL] [Abstract][Full Text] [Related]
13. The complement C3a and C5a signaling in renal diseases: a bridge between acute and chronic inflammation.
Buelli S; Imberti B; Morigi M
Nephron; 2024 Mar; ():. PubMed ID: 38452744
[TBL] [Abstract][Full Text] [Related]
14. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity.
Gorman DM; Li XX; Lee JD; Fung JN; Cui CS; Lee HS; Rolfe BE; Woodruff TM; Clark RJ
J Med Chem; 2021 Nov; 64(22):16598-16608. PubMed ID: 34762432
[TBL] [Abstract][Full Text] [Related]
15. New concepts on the therapeutic control of complement anaphylatoxin receptors.
Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors.
Yadav MK; Maharana J; Yadav R; Saha S; Sarma P; Soni C; Singh V; Saha S; Ganguly M; Li XX; Mohapatra S; Mishra S; Khant HA; Chami M; Woodruff TM; Banerjee R; Shukla AK; Gati C
Cell; 2023 Oct; 186(22):4956-4973.e21. PubMed ID: 37852260
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation.
Baelder R; Fuchs B; Bautsch W; Zwirner J; Köhl J; Hoymann HG; Glaab T; Erpenbeck V; Krug N; Braun A
J Immunol; 2005 Jan; 174(2):783-9. PubMed ID: 15634899
[TBL] [Abstract][Full Text] [Related]
18. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells.
Shivshankar P; Li YD; Mueller-Ortiz SL; Wetsel RA
FASEB J; 2020 Jun; 34(6):7540-7560. PubMed ID: 32301538
[TBL] [Abstract][Full Text] [Related]
19. Neutraligands of C5a can potentially occlude the interaction of C5a with the complement receptors C5aR1 and C5aR2.
Das A; Ghosh M; Gupta PK; Rana S
J Cell Biochem; 2023 Feb; 124(2):266-281. PubMed ID: 36565188
[TBL] [Abstract][Full Text] [Related]
20. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma.
Engelke C; Wiese AV; Schmudde I; Ender F; Ströver HA; Vollbrandt T; König P; Laumonnier Y; Köhl J
J Immunol; 2014 Dec; 193(11):5387-401. PubMed ID: 25355927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
